|
 "People with type 2 diabetes generally have a higher risk of
experiencing major adverse cardiovascular events. That's why we are
very excited about the results from LEADER (trial), which showed
that Victoza ... also reduces their risk of major adverse
cardiovascular events," Novo's Chief Science Officer Mads Krogsgaard
Thomsen said.
Novo Nordisk's shares jumped as much as 7 percent in the minutes
after the announcement.
(Reporting by Sabina Zawadzki; Editing by Elaine Hardcastle)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
